Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine
NCT00772473 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34
Last updated 2009-05-25
Summary
To assess CGRP levels in saliva through the evolution of migraine.
Conditions
- Headache, Migraine
Interventions
- OTHER
-
subjects personal triptan
Subjects will treat 1 migraine attack with their usual triptan
Sponsors & Collaborators
- collaborator INDUSTRY
-
Clinvest
lead OTHER
Principal Investigators
-
Roger K Cady, M.D. · Clinvest
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-02-29
- Primary Completion
- 2009-01-31
- Completion
- 2009-01-31
Countries
- United States
Study Locations
More Related Trials
-
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment
NCT03481400 ·Status: UNKNOWN ·Phase: NA
-
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies
NCT04503083 ·Status: UNKNOWN
-
The Role of CGRPand Nociceptin in Migraine
NCT00155129 ·Status: UNKNOWN
-
Salivary Inflammatory Markers in Tension Type Headache and Migraine
NCT03727672 ·Status: UNKNOWN
-
Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)
NCT00687947 ·Status: COMPLETED ·Phase: NA
-
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults
NCT07261371 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers
NCT00208065 ·Status: COMPLETED ·Phase: PHASE4
-
New Daily Persistent Headache Biomarkers Study
NCT04260087 ·Status: TERMINATED
-
Aspirin Resistance in Women With Migraine
NCT01257893 ·Status: WITHDRAWN ·Phase: NA
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
NCT06401642 ·Status: RECRUITING ·Phase: PHASE4
-
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
NCT07021859 ·Status: RECRUITING ·Phase: NA
-
The Effect of Sumatriptan and Placebo on CGRP Induced Headache
NCT03542357 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
NCT01445067 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
NCT01617941 ·Status: WITHDRAWN ·Phase: PHASE2
-
Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab
NCT04592952 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache
NCT01916395 ·Status: COMPLETED
-
Intracranial Pressure During Migraine
NCT03152305 ·Status: UNKNOWN
-
CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients
NCT02466334 ·Status: COMPLETED ·Phase: NA
-
Transcriptomic and Biochemical Changes During a Migraine Attack
NCT02468622 ·Status: COMPLETED
-
Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg
NCT05888766 ·Status: UNKNOWN
-
Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
NCT00358839 ·Status: COMPLETED ·Phase: NA
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750 ·Status: RECRUITING
-
Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women
NCT05854992 ·Status: COMPLETED
-
Cabergoline for Episodic Migraine
NCT07072910 ·Status: RECRUITING ·Phase: PHASE2
-
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
NCT02542605 ·Status: COMPLETED ·Phase: PHASE1